A5055721179- Systemic Lupus Erythematosus Research
- Reproductive System and Pregnancy
- Pregnancy and Medication Impact
- Assisted Reproductive Technology and Twin Pregnancy
- Pregnancy and preeclampsia studies
- Renal Diseases and Glomerulopathies
- Reproductive Biology and Fertility
- Platelet Disorders and Treatments
- Cardiovascular Issues in Pregnancy
- Prenatal Screening and Diagnostics
- T-cell and B-cell Immunology
- Monoclonal and Polyclonal Antibodies Research
- Ectopic Pregnancy Diagnosis and Management
- Blood Coagulation and Thrombosis Mechanisms
- Immunodeficiency and Autoimmune Disorders
- Maternal and fetal healthcare
- Heparin-Induced Thrombocytopenia and Thrombosis
- Reproductive Health and Technologies
- Endometriosis Research and Treatment
- Parvovirus B19 Infection Studies
- Liver Diseases and Immunity
- Diabetes and associated disorders
- Ovarian function and disorders
- Atherosclerosis and Cardiovascular Diseases
- Blood disorders and treatments
University of Toronto
2015-2025
Hospital for Sick Children
1992-2024
CReATe Fertility Centre
2017-2024
Mount Sinai Hospital
2023
CARE Fertility
2023
Translational Research in Oncology
2018-2023
Mount Sinai Hospital
2021
Mount Sinai Hospital
2004-2020
Children's Hospital of Eastern Ontario
2019
McGill University Health Centre
2019
Many patients with the antiphospholipid antibody syndrome and recurrent thrombosis receive doses of warfarin adjusted to achieve an international normalized ratio (INR) more than 3.0. However, there are no prospective data support this approach thromboprophylaxis.We performed a randomized, double-blind trial in which antibodies previous were assigned enough INR 2.0 3.0 (moderate intensity) or 3.1 4.0 (high intensity). Our objective was show that high-intensity effective preventing...
Objective To develop an evidence‐based guideline on contraception, assisted reproductive technologies ( ART ), fertility preservation with gonadotoxic therapy, use of menopausal hormone replacement therapy HRT pregnancy assessment and management, medication in patients rheumatic musculoskeletal disease RMD ). Methods We conducted a systematic review evidence relating to , preservation, lactation, populations, using Grading Recommendations Assessment, Development Evaluation methodology rate...
Background: Because systemic lupus erythematosus (SLE) affects women of reproductive age, pregnancy is a major concern. Objective: To identify predictors adverse outcomes (APOs) in patients with inactive or stable active SLE. Design: Prospective cohort. Setting: Multicenter. Patients: 385 (49% non-Hispanic white; 31% prior nephritis) SLE the PROMISSE (Predictors Pregnancy Outcome: Biomarkers Antiphospholipid Antibody Syndrome and Systemic Lupus Erythematosus) study. Exclusion criteria were...
Recurrent fetal loss has been well described in women with antiphospholipid antibodies. Such also often have other autoantibodies commonly found patients systemic lupus erythematosus. Treating them prednisone and aspirin may reduce the risk of loss.
To investigate which serologic and clinical findings predict adverse pregnancy outcome in patients with antiphospholipid antibody (aPL) to test the hypothesis that a pattern of variables can identify women at highest risk outcome.Women enrolled multicenter prospective observational study factors for aPL (lupus anticoagulant [LAC], anticardiolipin [aCL], and/or β2-glycoprotein I [anti-β2 GPI]) systemic lupus erythematosus (SLE) were recruited present study. Demographic, clinical, serologic,...
Objective. To compare live birth rates in women with recurrent pregnancy loss (RPL) and either autoantibodies or a coagulation abnormality, treated low molecular weight heparin plus aspirin (LMWH/ASA) ASA alone, to place our results context other randomized clinical trials (RCT) similar cohorts. Methods. The HepASA Trial was an RCT including patients history of RPL at least 1 the following: antiphospholipid antibody (aPL), inherited thrombophilia, antinuclear antibody. Treatment groups were...
Objective To develop an evidence‐based guideline on contraception, assisted reproductive technologies ( ART ), fertility preservation with gonadotoxic therapy, use of menopausal hormone replacement therapy HRT pregnancy assessment and management, medication in patients rheumatic musculoskeletal disease RMD ). Methods We conducted a systematic review evidence relating to , preservation, lactation, populations, using Grading Recommendations Assessment, Development Evaluation methodology rate...
To develop new antiphospholipid syndrome (APS) classification criteria with high specificity for use in observational studies and trials, jointly supported by the American College of Rheumatology (ACR) EULAR. This international multidisciplinary initiative included 4 phases: 1) Phase I, generation surveys literature review; 2) II, reduction modified Delphi nominal group technique exercises; 3) III, definition, further guidance real-world patient scenarios, weighting via consensus-based...
<h3>Objective</h3> To develop new antiphospholipid syndrome (APS) classification criteria with high specificity for use in observational studies and trials, jointly supported by the American College of Rheumatology (ACR) EULAR. <h3>Methods</h3> This international multidisciplinary initiative included four phases: (1) Phase I, generation surveys literature review; (2) II, reduction modified Delphi nominal group technique exercises; (3) III, definition, further guidance real-world patient...
BACKGROUND: Sperm DNA damage is prevalent amongst infertile men and has been shown to strongly impact adversely natural reproduction, intrauterine insemination-assisted reproduction a lesser degree IVF/ICSI fertilization. The objective of this study was examine further the relationship between sperm denaturation (DD) reproductive outcomes after ICSI. METHODS: We evaluated couples (n = 60) undergoing at single centre. DD assessed by flow cytometry analysis Acridine Orange-treated expressed as...
We previously reported that lupus anticoagulant (LAC) is the main predictor of poor pregnancy outcome in antiphospholipid antibody (aPL)-positive patients. sought to confirm this finding an independent group patients who were subsequently recruited into PROMISSE study.The study a multicentre, prospective, observational outcomes women with aPL and/or systemic erythematosus (SLE) enrolled from 2003 2015. All consecutive, aPL-positive completed their between April 2011 and January 2015 (after...
Objective Studies in mouse models implicate complement activation as a causative factor adverse pregnancy outcomes (APOs). We investigated whether of early predicts APOs women with systemic lupus erythematosus (SLE) and/or antiphospholipid (aPL) antibodies. Methods The PROMISSE Study enrolled pregnant SLE aPL antibodies (n=487) and healthy controls (n=204) at <12 weeks gestation evaluated them monthly. were: fetal/neonatal death, preterm delivery <36 because placental insufficiency or...
Background and objectives Kidney disease is a critical concern in counseling patients with lupus considering pregnancy. This study sought to assess the risk of renal flares during pregnancy women previous nephritis partial or complete remission, particularly those antidouble-stranded DNA antibodies low complement levels, new-onset stable/mildly active SLE. Design, setting, participants, & measurements We assessed (renal de novo kidney disease) associated predictors urine protein ≤1000 mg...